GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, announced it will release its second quarter 2025 financial results on July 28, 2025, after the U.S. markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. This event is crucial for investors and stakeholders interested in GeoVax's advancements in developing vaccines and immunotherapies for infectious diseases and cancer.
Participants can access the live conference call by registering here, with the webcast available on GeoVax's website under the Investor Relations section. The call will include a Q&A session, offering insights into the company's financial health and strategic direction. An archived version of the webcast will be available on the company's website for at least 90 days post-event.
GeoVax's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine currently in Phase 2 trials, targeting immunocompromised patients and those for whom current vaccines are insufficient. The company is also advancing a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, and developing a vaccine for Mpox and smallpox, with plans to proceed directly to a Phase 3 trial. These developments underscore GeoVax's commitment to addressing unmet medical needs and its potential impact on public health and the biotechnology industry.
